Related Experiment Videos
An open study of interferon in HIV-antibody-positive men
M E Ellis1, M R Haeney, J Craske
1Regional Department of Infectious Diseases, Monsall Hospital, Salford, UK.
AIDS (London, England)
|December 1, 1989
Abstract:
Alpha-2a-recombinant interferon (Roferon A) was given subcutaneously in a dose of 3 mega units twice weekly for 15-18 months to 14 HIV-antibody-positive, p24-antigen-negative men with minimal HIV-related disease. Interferon was well-tolerated and safe. Although there was either improvement or lack of deterioration initially in 22 out of 26 HIV disease markers, including lymphadenopathy, thrombocytopenic purpura and nail fungal infection, there were 11 instances of HIV disease indicators appearing during the study. At 15 months, six patients were withdrawn from the study because of clinical and immunological deterioration.